[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunosenescence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunosenescence":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,39,60,100,129,155,189,222,255,305,326],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644819","exploratory-study-on-infection-and-immunosenescence-based-on-an-elderly-clinical-cohort-100644819",false,"NCT07672522","Exploratory Study on Infection and Immunosenescence Based on an Elderly Clinical Cohort","Inclusion Criteria for the Healthy Control Group\n\n1. No clinical symptoms suggestive of infection, including fever, cough, dyspnea, fatigue, or myalgia.\n2. No abnormal physical signs, including lymphadenopathy, hepatomegaly, splenomegaly, or skin rash.\n3. Normal laboratory test results, including complete blood count (CBC), C-reactive protein (CRP), and liver and renal function tests.\n4. Healthy adults without underlying chronic diseases, no history of infectious diseases within the previous 6 months, and generally normal cognitive function.\n5. Male or female.\n6. Able to understand the study procedures and voluntarily provide written informed consent.\n\nInclusion Criteria for the Infection Group 1.Age: 60 years or older; no gender restrictions. 2. Clinically diagnosed with an infectious disease by the treating physician. 3. The participant provides informed consent and signs the relevant documents.\n\n\\-------------- Exclusion Criteria for the Healthy Control Group\n\n1. Refusal to participate in the study;\n2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nExclusion Criteria for the Infection Group\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, tumor, or other conditions).\n2. Positive culture results are determined by the clinician to be due to colonization or contamination rather than infection.\n3. Refusal to participate in the study.\n4. Patients in critical or severe conditions who are unable to cooperate with sample collection.\n5. Other conditions deemed unsuitable for inclusion as determined by the researchers.",true,"ALL","60 Years",{"count":19,"type":20},484,"ESTIMATED","5 Years","OBSERVATIONAL","This prospective observational cohort study aims to investigate the relationship between immunosenescence and infectious diseases in older adults. Individuals aged 60 years and older, including elderly patients with infections and healthy controls, will be enrolled and followed longitudinally.\n\nClinical information, laboratory test results, and health assessment data will be collected. Biological specimens, including peripheral blood, urine, stool, sputum, and nasopharyngeal swabs, will be obtained during enrollment and follow-up. Participants will undergo regular assessments of health status, infection events, and aging-related clinical characteristics.\n\nThe study will evaluate age-related changes in immune function, immune cell composition, immune receptor repertoires, epigenetic characteristics, metabolic profiles, and respiratory and gut microbiota. By integrating clinical and multi-omics data, the study aims to identify biomarkers associated with immunosenescence, susceptibility to infection, disease severity, and clinical outcomes in older adults.\n\nThe results are expected to improve understanding of the mechanisms linking aging, immune dysfunction, and infectious diseases, and to support the development of predictive models and preventive strategies for infection management and healthy aging in elderly populations.",[25],"Immunosenescence","RECRUITING","2026-06-26",{"date":29,"type":30},"2026-06-29","ACTUAL",{"date":32,"type":30},"2024-11-29",{"date":34,"type":20},"2029-10-30",{"name":36,"class":37},"Huashan Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100643096","research-project-on-the-interaction-between-immune-function-and-infectious-diseases-in-older-adults-and-the-development-of-prevention-and-control-strategies-100643096","NCT07644962","Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies","Inclusion Criteria:\n\n\\- General Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.\n2. Male or female.\n3. Able to understand the study and voluntarily provide written informed consent.\n\nInfection Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older, regardless of sex.\n2. Patients with an infectious disease diagnosed by a qualified clinician.\n\nExclusion Criteria:\n\n* General Cohort Exclusion Criteria\n\n  1. Refusal to participate in this study.\n  2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nInfection Cohort Exclusion Criteria\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).\n2. Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.\n3. Refusal to participate in this study.\n4. Critically ill patients or those unable to cooperate with specimen collection procedures.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.",{"count":46,"type":20},23000,"As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.\n\nBuilding upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.",[49,25,50],"Infectious Diseases","Aging","NOT_YET_RECRUITING","2026-06-08",{"date":54,"type":30},"2026-06-12",{"date":56,"type":20},"2026-06-09",{"date":58,"type":20},"2029-12-30",{"name":36,"class":37},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":68,"minAge":69,"maxAge":17,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":38},"100619166","skin-inflammation-in-perimenopause-a-probiotic-intervention-proof-of-concept-trial-100619166","NCT07341087","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial (SIPPI)","SIPPI","Inclusion Criteria:\n\n1. Female, aged 40-60 years.\n2. Self-reported or clinician-diagnosed non-infectious, non-autoimmune inflammatory skin condition affecting the face (e.g., rosacea, acne, eczema).\n3. Willing and able to consume a daily oral intervention (2x 65 ml probiotic drinks or skimmed milk) for 8 weeks.\n4. Willing and able to provide sufficient blood, skin and stool samples at baseline and end-of-study (Week 8). Participants unable to provide adequate blood sample volumes will not be able to start the intervention.\n5. Willing and able to provide a photograph of the facial area, with all images anonymised for study purposes.\n6. Able to comply with study procedures, including attending clinic visits at KCL.\n7. Have access to a refrigerator at home and be able to store the study product(s) safely after collection (i.e., travel time allows safe storage).\n8. Capable of providing written informed consent.\n9. Have sufficient proficiency in English to complete study questionnaires and assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Inability or unwillingness to comply with study protocol requirements (e.g., clinic visits, sample provision, daily consumption of study drink)\n3. Unwilling to record dietary intakes using handwritten diet diaries\n4. Not fluent in the English language\n5. Is planning on international travel during the study period\n6. Current participation in another interventional clinical trial or having received an investigational\u002Fpharmaceutical product within the past 3 months.\n7. Known allergy or intolerance to dairy products, skimmed milk, or probiotic drinks containing Lactobacillus species.\n8. Currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months.\n9. BMI \\\u003C18.5kg\u002Fm2 or \\> 35kg\u002Fm2.\n10. Unintentional weight loss greater than 4 kg in the 3 months prior to enrolment.\n11. History of substance abuse or alcoholism (alcohol intake \\>50 units\u002Fweek) within the last 12 months.\n12. Current smokers, or individuals who quit smoking in the last 6-months.\n13. Fasting glucose \\>7mmol\u002Fl (finger prick test at baseline clinic).\n14. Active skin infection requiring systemic antibiotics, antivirals, or antifungals within the past 4 weeks.\n15. Major gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease, short bowel syndrome) or history of significant gastrointestinal surgery (excluding appendectomy or cholecystectomy).\n16. Known immunodeficiency (e.g., HIV, immunosuppressive therapy, systemic corticosteroids \\>10 mg\u002Fday prednisolone equivalent).\n17. History of malignancy or clinically significant non-malignant skin conditions within the past 5 years (except adequately treated basal cell carcinoma).\n18. Serious medical conditions that, in the opinion of the investigator, would compromise safety or interfere with study outcomes (e.g., uncontrolled diabetes, advanced cardiovascular, hepatic, or renal disease, active cancer, autoimmune conditions).\n19. Women with a history of severe psychiatric illness that would limit adherence to study requirements.\n20. Current use of probiotics, prebiotics, or antibiotics within 4 weeks prior to baseline.\n21. Current use of systemic corticosteroids, or other immunosuppressive\u002Fimmunomodulatory therapies within the past 3 months.\n22. Currently receiving, or having received, phototherapy (e.g., UVB, PUVA, laser\u002Flight-based treatments, including at home treatments) for any skin condition within the past 3 months.\n23. Currently receiving, or having received, systemic dermatology treatments likely to affect skin inflammation or immune response within the past 3 months (e.g., isotretinoin, methotrexate, cyclosporine, biologics such as TNF, IL-17, IL-23 or IL-4\u002FIL-13 inhibitors).\n24. Currently receiving, or having received, topical treatments likely to significantly alter skin inflammation within the past 3 months (e.g., high-potency topical corticosteroids, topical calcineurin inhibitors such as tacrolimus or pimecrolimus, topical retinoids, or photodynamic therapy).\n25. Currently using, or have used, probiotic skincare (e.g., topical creams and serums) within the past 3 months.\n26. Currently receiving, have undergone, or plan to undergo cosmetic skin procedures (e.g., chemical peels, laser therapy, dermal fillers, microneedling) within the 3 months prior to, or within 3 months after the first (baseline) visit.\n27. Currently using, or have used, hormonal contraceptives or treatments known to exacerbate skin conditions, including Mirena (levonorgestrel-releasing intrauterine system), oral progesterone-only contraceptives (e.g., mini-pill), and synthetic progestogens (e.g., norethisterone) within the past 3 months.","FEMALE","40 Years",{"count":71,"type":20},30,"INTERVENTIONAL",[74],"NA","This study will explore whether a daily probiotic drink containing Lactobacillus casei Shirota (LcS) can help improve immune function and reduce inflammation in women going through the menopausal transition. Hormonal changes during this stage of life can affect the immune system, gut health, and skin, sometimes leading to increased inflammation or conditions such as eczema, acne or rosacea.\n\nParticipants will consume either a low-sugar LcS probiotic drink or a skimmed milk control drink every day for eight weeks. The study will assess markers of immune ageing, inflammation, skin health, wellbeing, and hormone levels. The results will help determine whether a safe, non-hormonal probiotic approach may support immune and skin health during the menopausal transition.",[77,25,78,79,80,81,82,83],"Skin Inflammation","Inflammation","Skin Health","Eczema","Rosacea","Acne","Menopause",[85,86,87,88,89,90],"Probiotics","Lactobacillus casei Shirota","Immune ageing","Gut-skin axis","Skin health","Menopausal transition","2026-05-05",{"date":93,"type":30},"2026-05-08",{"date":95,"type":30},"2026-04-28",{"date":97,"type":20},"2027-11-01",{"name":99,"class":37},"King's College London",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":15,"sex":16,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":72,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":38},"100611380","interferon-reference-for-older-people---refipa-study-100611380","NCT07239830","Interferon Reference for Older People - REFIPA Study","Reference Values Determination of Nasal and Blood Interferon Scores in Uninfected Older Subjects REFérence Interféron Older Subjects (Older People Interferon Reference) - REFIPA Study","REFIPA","Inclusion Criteria:\n\n* Subject aged 80 or over\n* Patient admitted to the Charpennes hospital day unit or outpatient clinic for follow-up OR accompanying patient who receive care at the Charpennes geriatric hospital OR subject recruited through the local press\n* Weight greater than or equal to 45 kg\n* Subject living in the Lyon metropolitan area\n\nExclusion Criteria:\n\n* Subjects with symptoms of active infection (symptom questionnaire or temperature \\> 37.5°C).\n* Subjects with an autoimmune disease linked to a dysregulated interferon response.\n* Subjects participating in another interventional study involving an exclusion period that is still ongoing or that may interfere with the present protocol.\n* Subjects deprived of their liberty by judicial or administrative decision\n* Subjects receiving psychiatric care\n* Adults subject to legal protection measures (guardianship, curatorship)\n* Subjects not affiliated with a social security scheme or beneficiaries of a similar scheme","80 Years",{"count":110,"type":20},62,[74],"The diagnosis of respiratory viral infections is mainly based on PCR tests targeting the DNA or RNA of suspected viruses, including SARS-CoV-2, RSV and influenza viruses. However, this method is limited because it only tests for a small number of viruses, while many other pathogens can cause similar symptoms. As a result, respiratory viral infections are often underdiagnosed because not all possible viruses are systematically tested for.\n\nAnother limitation of PCR tests is that they can detect residual viral genetic material long after the infection has ended, making it difficult to distinguish between an active infection and a past one. Viral load can help interpret the result, but it is not always reliable. It is therefore essential to have complementary markers that can indicate whether the detected virus is still in the active replication phase.\n\nAn innovative approach is to measure the host's immune response, in particular the production of type I interferons (IFN-I), which are markers of active viral infection. Studies have shown that joint analysis of the IFN-I\u002FIII response and PCR tests improves the detection of viral respiratory infections by better discriminating between active infections. This method shows promise for refining diagnosis, particularly in cases where the viral load is low or ambiguous.\n\nThese advances are particularly important for older patients, in whom viral infections have a severe impact. Ageing leads to a decline in immune function (immunosenescence), including a reduction in IFN-I production. This alteration could further complicate the interpretation of immune biomarkers in older people, highlighting the need to establish reference values specific to this population.\n\nIn this context, the RESPIGERIA study (compliance with MR004 No. 24-5127) was launched to evaluate the IFN response in geriatric hospitalised patients with respiratory viral infections. However, there is still a lack of reference data on the IFN response in uninfected older individuals. Establishing a baseline IFN score in this population is essential in order to adapt diagnostic tools to age-related specificities.",[25,114],"Uninfected Older",[116,117,118,119],"respiratory viral infection","Type I Interferon response","Older People","host-based response diagnostic test","2026-04-02",{"date":122,"type":30},"2026-04-08",{"date":124,"type":30},"2025-12-02",{"date":126,"type":20},"2026-12-03",{"name":128,"class":37},"Hospices Civils de Lyon",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":72,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100629610","the-impact-of-aerobic-exercise-program-on-immunosenescence-institutionalized-older-adults-100629610","NCT07476911","The Impact of Aerobic Exercise Program on Immunosenescence Institutionalized Older Adults","The Impact of Aerobic Exercise Program on Immunosenescence in Institutionalized Older Adults: a Study Protocol for Randomized Controlled Trials","Inclusion criteria:\n\nParticipants must be aged 60 years or older and institutionalized. Studying institutionalised older adults ensures greater uniformity in diet, daily routines, behaviours, and environmental exposures, thereby minimising the impact of external factors other than the exercise intervention.\n\nExclusion criteria:\n\nParticipants will be excluded if they have acute conditions that may affect their immune or inflammatory responses. These conditions include recent trauma or surgery (within the previous six months), recent blood transfusions (within the previous month), acute infections (such as respiratory, gastrointestinal, or urinary infections), recent vaccinations, and the use of medications that may interfere with immune responses (such as immunomodulators, systemic corticosteroids, methotrexate, and biologics).",{"count":137,"type":20},40,[74],"Background: Immunosenescence is an age-related decline in immune function, associated with chronic low-grade inflammation, increased morbidity, and functional impairment in older adults. Aerobic exercise has been proposed as an effective non-pharmacological strategy to counteract these alterations; however, evidence from randomized-controlled trials (RCTs), particularly in institutionalized elderly populations, remains scarce and methodologically limited.\n\nObjective: This study protocol aims to investigate the effects of short- and medium-term aerobic exercise programs on immunosenescence in institutionalized older adults, as well as to analyze the impact of a detraining period and a subsequent reintervention.\n\nMethods: A stratified RCT will be conducted with institutionalized adults aged ≥60 years, randomly allocated to an aerobic exercise group or a control group. The intervention consists of a supervised 12-week moderate-intensity aerobic exercise program (three sessions\u002Fweek), followed by a 4-week detraining period and a 4-week reintervention. Assessments will be performed at five time points. Primary outcomes include immunological and analytical parameters assessed by spectral flow cytometry and multiplex cytokine analysis. Secondary outcomes include anthropometry, functional capacity, hemodynamic parameters, heart rate variability, and psychological indicators.\n\nExpected Results: Aerobic exercise is expected to induce favorable immunological adaptations, partially reverse immunosenescence, and improve functional and psychosocial outcomes.",[25,50],[142,143,50,144,145,25],"Aerobic exercise","Elderly","Institutionalized","Immune system","2026-03-12",{"date":148,"type":30},"2026-03-17",{"date":150,"type":20},"2026-03-02",{"date":152,"type":20},"2026-10-30",{"name":154,"class":37},"Instituto Politécnico de Castelo Branco",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":72,"phases":165,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":38},"100628525","phase-1-precision-microbiota-interventions-for-senoreduction-trial-100628525","NCT07462767","Precision Microbiota Interventions for Senoreduction Trial","Geroprotective Precision Medicine Strategies in PWH That Use Alcohol","PreMIS","Inclusion Criteria:\n\n* Age ≥40 years\n* People with HIV\n* Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)\n\nExclusion Criteria:\n\n* Probiotic use in past 3 months\n* Recent antibiotics or immunosuppressives\n* Allergy to study products\n* Pregnancy or breastfeeding\n* Inability to comply",{"count":164,"type":20},160,[166,167],"PHASE1","PHASE2","People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.",[170,171,50,25],"HIV Infections","Alcohol Drinking",[173,174,25,175,176,177,178,179],"People with HIV","Alcohol use","Senescence","Microbiome","Probiotic","Blueberry extract","Crossover trial","2026-03-05",{"date":182,"type":30},"2026-03-10",{"date":184,"type":20},"2026-04-01",{"date":186,"type":20},"2029-12-01",{"name":188,"class":37},"Louisiana State University Health Sciences Center in New Orleans",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":199,"studyType":22,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":38},"100620426","effect-of-oral-supplement-on-influenza-vaccine-long-term-response-100620426","NCT07357467","Effect of Oral Supplement on Influenza Vaccine Long-term Response","Effect of Oral Supplement Intervention on Influenza Vaccine Long-term Efficacy: a Follow-up Study","EOSIIVE-F","Inclusion Criteria:\n\n1. Originally assigned to either the TUDCA supplementation group or placebo control group\n2. No influenza vaccination or other vaccines received between April 2025 and December 2025\n3. Willing to participate in this follow-up study and sign supplementary informed consent\n4. Stable health condition\n\nExclusion Criteria:\n\n1. Started using immunosuppressants or hormonal medications after the original study\n2. Experienced serious illness or hospitalization within the past month, or planning surgery soon\n3. Experienced fever, cold, severe diarrhea, or taken influenza antiviral medications within the past month\n4. Unable or unwilling to participate in blood collection\n5. Lost to follow-up or unable to contact","70 Years",{"count":71,"type":20},"1 Year","This is a follow-up study of a previously completed randomized controlled trial (NCT06827873) that investigated the effects of oral supplements on influenza vaccine response in adults aged 60-70 years. The original study was completed in April 2025, with participants receiving either TUDCA (Tauro Ursodesoxy Cholic Acid) supplementation, fatty acid supplementation, or placebo during influenza vaccination.\n\nThe primary objectives of this follow-up study are to:\n\n1. Evaluate the durability of vaccine-induced antibody responses approximately 8 months post-vaccination\n2. Assess the persistence of immune memory cells, particularly long-lived plasma cells and memory B cells\n3. Compare long-term immune responses between the TUDCA supplementation group and placebo group\n\nThis observational follow-up involves a single visit where participants will:\n\n1. Provide one blood sample for antibody and immune cell analysis\n2. No intervention or vaccination will be administered\n\nThe study will specifically focus on B cell subsets through flow cytometry analysis, including total B cells, memory B cells, plasma cells, and long-lived plasma cells. This research aims to determine whether TUDCA supplementation can enhance the durability of vaccine-induced immunity in older adults.",[202,25],"Influenza",[204,205,206,207,208,209,210,211,212],"Tauroursodeoxycholic Acid (TUDCA)","Influenza Vaccine","Antibody","Memory B Cells","Long-lived Plasma Cells","Elderly Adults","Humoral Immunity","Nutritional Immunomodulation","Bile Acids","2026-01-20",{"date":215,"type":30},"2026-01-22",{"date":217,"type":20},"2026-03",{"date":219,"type":20},"2026-07",{"name":221,"class":37},"Tsinghua University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":72,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":38},"100592997","vital-vaccination-immunity-time-restricted-eating-aging-and-lifestyle-100592997","NCT07000708","VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle","VITAL","Inclusion Criteria:\n\n* Male and female participants, enrolled in a 1:1 ratio\n* Age 60-85 years\n* Body mass index (BMI) 20-35 kg\u002Fm²\n* Capacity to give informed consent\n* Existing health insurance to allow evaluation and treatment of any incidental findings\n* Usual daily eating window \\> 11 hours\n* First meal of the day before 10:00 AM\n* Willingness to receive seasonal influenza and COVID-19 vaccination and proof of scheduled appointment\n* Willingness and ability to follow a prescribed TRE dietary regimen (8-hour daily eating window; 16-hour fast without any caloric intake)\n* Appointment for simultaneous influenza and COVID-19 vaccination pre-arranged with primary care physician and coordinated with study team to align with TRE intervention\n\nExclusion Criteria:\n\n* Any vaccination (especially influenza and\u002For COVID-19) within 6 months before the intervention start\n* Vaccinations not related to the study, administered during the study period from V0 to V4\n* History of influenza infection within 6 months prior to initiation of the study intervention\n* History of severe adverse reactions to prior vaccinations\n* Use of pharmacological weight-loss agents (e.g., semaglutide)\n* Diabetes mellitus under ongoing pharmacological treatment\n* Symptoms of systemic inflammatory or autoimmune disease\n* Immunosuppression (including use of immunosuppressive drugs)\n* Severe hypertension (systolic \\> 180 mmHg or diastolic \\> 110 mmHg)\n* Diseases or functional disorders which, in the opinion of the study physician, preclude participation in the study\n* Participation in any fasting intervention (e.g., TRE, alternate-day fasting, 5:2, 18:6) within 6 months before enrollment\n* Participation in another diet or weight-loss program (e.g., intensive athletic training)\n* Night-shift or rotating-shift work\n* Severe, active, or unstable medical conditions requiring treatment\n* Postoperative recovery phase\n* Antibiotic therapy within 3 months before enrollment\n* Acute or chronic infections\n* Therapeutic or medically prescribed special diets\n* Vegan diet\n* Current smoker\n* Weight change \\> 2 kg in the month before enrollment\n* Known substance, drug, or alcohol abuse\n* Anemia\n* Claustrophobia\n* Legal incapacity or any other circumstance that prevents full understanding of the nature, importance, and implications of the study","85 Years",{"count":231,"type":20},24,[74],"The aim of this study is to investigate the effects of a four-week time-restricted eating (TRE) intervention on autophagy, immune function, and vaccine response to a seasonal influenza and COVID-19 vaccines in older healthy subjects.",[235,25,236],"Vaccination","Metabolism",[238,239,240,241,242,243,244,245],"fasting","vaccination","intermittent fasting","time-restricted eating","influenza","immunity","aging","immunosenescence","2025-09-17",{"date":248,"type":30},"2025-09-18",{"date":250,"type":30},"2025-09-10",{"date":252,"type":20},"2027-01",{"name":254,"class":37},"Charite University, Berlin, Germany",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":15,"sex":16,"minAge":263,"maxAge":108,"enrollmentInfo":264,"targetDuration":266,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":282,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":38},"100464026","biobank-and-brain-health-in-bordeaux-100464026","NCT05322343","Biobank and Brain Health in Bordeaux.","Biobank and Brain Health in Bordeaux. A Population-based Cohort to Study the Biology of Brain and Cognitive Aging in Young Seniors","B-cube","Inclusion Criteria:\n\nFor the main study:\n\n1. live in Bordeaux metropolitan area,\n2. be between 55 and 80 years old (included),\n3. selected in terms of socioeconomic level, according to a sampling strategy by age groups and income categories representative of the general population between 55 and 80 years of age\n4. be affiliated with the social security system,\n5. agree to take a blood sample for the biobank.\n\nFor the MRI sub-study: be between 55 and 75 years old (included). Inclusion criteria for the immune response substudy: be 70 years of age or older or participate in the MRI study; agree to take a supplemental blood sample for this substudy.\n\nExclusion Criteria:\n\nFor the main study: persons under guardianship (or more generally under protection), unable to give consent to participate.\n\nFor the MRI sub-study: have a contraindication to MRI examination (pacemaker, a valve prosthesis or any other internal electrical\u002Fmagnetic device; history of neurosurgery or aneurysm; claustrophobia; presence of metal fragments in the eyes, brain or spinal cord).","55 Years",{"count":265,"type":20},2050,"12 Months","B cube is a new generation cohort to study the determinants and natural history of brain aging, using molecular epidemiology, in a representative sample (N=2000) of the general population from the age of 55 (the approximate age of onset of the first cognitive disorders and a target population particularly receptive to prevention messages). Special interest will be given to nutrition, a promising environmental exposure for prevention.",[269,50,270,25,271,272,273,274,275,276,277,278,279,280,281],"Brain","Cognitive Aging","Mental Processes","Mental Disorders","Neurocognitive Disorders","Cognition","Brain Diseases","Dementia","Alzheimer Disease","Mental Health","Behavioral Symptoms","Depression","Anxiety",[283,284,285,286,287,288,289,290,291,292,293,294,295],"Epidemiologic Methods","Risk factors","Public Health","Environmental Exposure","Exposome","Dietary Exposure","Diet","Food and Nutrition","Nutritional Status","Metabolomics","Systems biology","Environmental Biomarkers","Inflammation Mediators","2025-08-08",{"date":298,"type":30},"2025-08-11",{"date":300,"type":30},"2022-03-22",{"date":302,"type":20},"2030-03-22",{"name":304,"class":37},"University Hospital, Bordeaux",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":197,"enrollmentInfo":312,"targetDuration":4,"studyType":72,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":38},"100585819","the-impact-of-nicotinamide-mononucleotide-sustained-release-tablets-on-immunosenescence-and-metablism-in-middle-aged-and-elderly-individuals-with-metabolic-disorders-100585819","NCT06907329","The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.","Inclusion Criteria:\n\n1. Age 50-70 years with overweight or obesity (BMI 24kg\u002Fm2);\n2. At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \\\u003C7% without glucose-lowering drug therapy;\n3. Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with tumours;\n2. Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);\n3. Severe cardiovascular disease or cardiac insufficiency;\n4. Systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg;\n5. Chronic obstructive pulmonary disease;\n6. Chronic active hepatitis or cirrhosis;\n7. Chronic renal insufficiency;\n8. Stroke patients\n9. Severe haematological diseases;\n10. Infectious diseases;\n11. Mental illness;\n12. Other conditions that, in the opinion of the investigator, may affect the results of the study;\n13. Those who have used NMN or other anti-aging agents within six months.\n14. Premenopausal woman\n15. ALT, AST values are more than three times higher than the upper limit of the normal reference range","50 Years",{"count":313,"type":20},126,[74],"The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.",[25,236],"2025-07-02",{"date":319,"type":30},"2025-07-08",{"date":321,"type":30},"2025-06-05",{"date":323,"type":20},"2027-03-31",{"name":325,"class":37},"Qing Su",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":15,"sex":16,"minAge":69,"maxAge":108,"enrollmentInfo":333,"targetDuration":4,"studyType":72,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":38},"100391336","phase-2-thymus-regeneration-immunorestoration-and-insulin-mitigation-extension-trial-100391336","NCT04375657","Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial","TRIIM-X","Inclusion Criteria:\n\n* Male or female volunteers\n* Aged 40 to 80 years, inclusive\n* All ethnicities\n* Able to participate in 12-month study\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Malignancies or high risk of malignancy, as suggested by familial risk or personal medical history\n* Premenopausal women\n* Postmenopausal women on HRT\n* IGF-1 levels \\\u003C 90 ng\u002Fml or \\>300 ng\u002Fml\n* Diagnosed or suspected growth hormone resistance\n* Known growth hormone deficiency based on stimulation testing\n* Pre-existing carpal tunnel syndrome\n* Significant arthritis\u002Farthralgia\u002Fjoint swelling\n* Bradycardia (\\\u003C55 bpm), significant hypertension (systolic \\>160 mmHg, or diastolic \\>90 mmHg) despite treatment, serious angina, or other serious cardiovascular disease or cardiovascular disease risk factors\n* Excessive skin growths (e.g., flat warts) without cryosurgical options\n* BMI of 35 or greater\n* PSA level above the age-adjusted normal range for reasons other than confirmed prostatitis\n* Testosterone levels above the upper limit of normal\n* Levels of C-reactive protein (CRP) above the upper limit of normal\n* Type 1 or pre-existing Type 2 diabetes\n* Uncorrected hypothyroidism\n* HIV infection\n* Allergy or other sensitivity to study medications\n* Other unstable medical conditions\n* Use of GH within the last 5 years\n* Participation in a clinical research trial within 30 days prior to enrollment\n* Use of chronic glucocorticoid therapy\n* Unwilling to discontinue androgen supplementation if testosterone levels are above the upper limit of normal\n* Ongoing treatment with carbonic anhydrase inhibitors\n* Ketogenic diet, calorie-restricted diet, or prolonged fasting, without willingness to discontinue these diets or adhere to an alternative diet during the study\n* Alcoholism or drug addiction\n* Smoking or unwillingness to quit smoking\n* Cognitive impairment, illiteracy, inability or unwillingness to give voluntary informed consent",{"count":334,"type":20},85,[167],"The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.\n\nThe study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.\n\nThe objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.",[338,25],"Epigenetic Aging","2025-05-05",{"date":341,"type":30},"2025-05-07",{"date":343,"type":30},"2020-11-23",{"date":345,"type":20},"2025-12",{"name":347,"class":348},"Intervene Immune, Inc.","INDUSTRY"]